MetLife Inc (MET)

Sep 24, 2026

UBS AG has priced contingent income auto-callable securities linked to MetLife, Inc. common stock at a 100.00% public issue price, with an anticipated maturity around October 5, 2029. The estimated initial value for investors ranges from $944.10 to $974.10, and these securities will not be listed on any exchange. UBS Securities LLC will acquire the securities at a discount and resell them, with the estimated initial value reflecting UBS's internal pricing models and various market factors.

Sep 23, 2026

MetLife (NYSE:MET) has re-entered the market spotlight due to a shifting bond-market environment, which is drawing attention to insurers and their investment portfolios. The company's focus on employee benefits, insurance, and retirement products is particularly relevant in this context. The article suggests that future company announcements will be key to validating the current interest in MetLife.

Sep 21, 2026

Nykredit A/S recently acquired 86,368 shares of The Hartford Insurance Group, Inc. (NYSE:HIG) for approximately $11.45 million. The Hartford exceeded its Q2 earnings expectations with $3.42 EPS and $7.26 billion in revenue. The company maintains a "Hold" consensus rating from analysts with an average price target of $149.07 and declared a $0.60 quarterly dividend.

Sep 21, 2026

Bank of America Corp DE recently acquired 618,267 shares of Unum Group (UNM) worth approximately $55.3 million, making it one of several institutional investors increasing their stakes. Unum Group reported strong quarterly earnings, matched analyst estimates, and announced a $1 billion share-repurchase program and an increased quarterly dividend. Despite some insider selling, analysts maintain a "Moderate Buy" consensus for UNM, with the stock trading near its 52-week high.

Sep 20, 2026

MetLife, Inc. (NYSE:MET) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $102.77, exceeding its current share price of $97.08. The company recently surpassed quarterly earnings estimates, reporting $2.43 EPS against a $2.30 consensus, and saw a 10.5% year-over-year revenue increase. Additionally, MetLife announced a $3 billion share repurchase program and a quarterly dividend of $0.5925 per share, representing a 2.4% yield.

Sep 19, 2026

PTC (NASDAQ:PTC) is back in the market spotlight due to the increasing relevance of manufacturing digitization, which ties design and lifecycle software to industrial efficiency. The article highlights PTC's distinct product-development and industrial software perspective, emphasizing that its operational model and specific business angle are more important than broad sector trends. The next crucial step for PTC will be providing company-specific evidence to confirm whether this renewed attention translates into operational substance.

Sep 17, 2026

ChronoScale Holdings Corporation announced an extension of the maturity date for its $2.0 million term loan with B. Riley Commercial Capital, LLC. The amendment, effective September 12, 2026, pushes the maturity to November 12, 2026, and recognizes the potential sale of guarantor Ekso Bionics, Inc. as a Permitted Disposition. All other key terms of the original agreement remain unchanged.

Sep 16, 2026

MetLife Inc. (MET) stock dropped 1.01% to $97.23 on Wednesday, breaking a five-day winning streak, despite an overall tough trading session where the S&P 500 and Dow Jones also declined. The article highlights that MetLife's stock performance still outpaced its competitors despite the daily loss.

Sep 16, 2026

Bank of America Corp DE has acquired a significant stake in MetLife, purchasing over 5.38 million shares valued at approximately $455.4 million, representing 0.84% of the company. This move comes as institutional investors collectively own nearly 95% of MetLife. Analysts maintain a "Moderate Buy" rating for MetLife, with an average price target of $102.77, following better-than-expected quarterly earnings and a recent dividend announcement.

Sep 14, 2026

The $4.1 billion sale of Charlotte-based insurer Brighthouse Financial to Aquarian Holdings has been delayed. The original closing deadline this month was missed because regulators in three states have yet to approve the transaction. This news comes as another Brighthouse executive exits and the company previously posted a significant quarterly loss.

Sep 14, 2026

NewEdge Advisors LLC significantly increased its stake in MetLife, Inc. by 20.1% during the second quarter, now holding 74,002 shares valued at $6.26 million. Institutional investors collectively own a substantial 94.99% of MetLife's stock, reflecting strong confidence. The company also reported better-than-expected quarterly EPS, a 10.5% year-over-year revenue increase, a $0.5925 quarterly dividend, and authorized a $3 billion share-repurchase program.

Sep 14, 2026

Corient Private Wealth LP reduced its stake in MetLife, Inc. (NYSE:MET) by 20.5% in the second quarter, now owning 400,337 shares valued at $33,873,000. Despite this, other institutional investors like California State Teachers Retirement System and BlackRock Inc. significantly increased their holdings. MetLife recently reported strong quarterly earnings, surpassing analyst estimates, and announced a $3.00 billion share repurchase plan, alongside a quarterly dividend payment.

Sep 14, 2026

Corient Private Wealth LP significantly increased its stake in The Travelers Companies, Inc. by 1,562.2% during the second quarter, now owning 109,936 shares valued at $36.29 million. Other institutional investors also adjusted their positions, with overall institutional ownership at 82.45%. The company recently reported strong earnings, beating consensus estimates, and declared a quarterly dividend of $1.25.

Sep 12, 2026

Amundi significantly increased its stake in Caris Life Sciences (NASDAQ:CAI) by 5,709.5% in the second quarter, purchasing 1,197,392 shares and bringing its total holdings to 1,218,364 shares valued at $21.7 million. This move comes amidst mixed analyst ratings, with a consensus "Hold" rating and an average price target of $26.50. Additionally, Caris Life Sciences authorized a $100 million share-repurchase program, while its president sold shares to cover tax obligations.